These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1628919)

  • 1. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Experimental drug policies in Canada.
    Int J Technol Assess Health Care; 1992; 8(2):367-8. PubMed ID: 1628919
    [No Abstract]   [Full Text] [Related]  

  • 2. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
    Int J Technol Assess Health Care; 1995; 11(3):628-9. PubMed ID: 7591560
    [No Abstract]   [Full Text] [Related]  

  • 3. Report from the Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Satellite symposium to the eighth annual meeting of the International Society of Technology Assessment in Health Care (ISTAHC).
    Int J Technol Assess Health Care; 1993; 9(2):311-2. PubMed ID: 8458709
    [No Abstract]   [Full Text] [Related]  

  • 4. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Leukoreduction: the techniques used, their effectiveness, and costs.
    Int J Technol Assess Health Care; 1998; 14(3):586-8. PubMed ID: 9780546
    [No Abstract]   [Full Text] [Related]  

  • 5. Evaluation of the Canadian Coordinating Office for Health Technology Assessment.
    Battista RN; Feeny DH; Hodge MJ
    Int J Technol Assess Health Care; 1995; 11(1):102-16. PubMed ID: 7706007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Reuse of single-use cardiac catheters.
    Int J Technol Assess Health Care; 1991; 7(4):637-8. PubMed ID: 1778708
    [No Abstract]   [Full Text] [Related]  

  • 7. TENS: CCOHTA (Canadian Coordinating Office for Health Technology Assessment) responds.
    Menon D
    Leadersh Health Serv; 1996; 5(1):12-3. PubMed ID: 10154220
    [No Abstract]   [Full Text] [Related]  

  • 8. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Magnetic field strength issues in magnetic resonance imaging (MRI).
    Int J Technol Assess Health Care; 1993; 9(4):590-3. PubMed ID: 8288436
    [No Abstract]   [Full Text] [Related]  

  • 9. Reports from the Canadian coordinating office for Health Technology Assessment (CCOHTA).
    Int J Technol Assess Health Care; 1999; 15(2):436-7. PubMed ID: 10507200
    [No Abstract]   [Full Text] [Related]  

  • 10. Finance issue brief: mandated benefits: off-label drug coverage requirements: year end report-2003.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-9. PubMed ID: 14870745
    [No Abstract]   [Full Text] [Related]  

  • 11. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada.
    Int J Technol Assess Health Care; 1995; 11(4):796-7. PubMed ID: 8567213
    [No Abstract]   [Full Text] [Related]  

  • 12. Challenges, choices, and Canada.
    Sanders JM
    Int J Technol Assess Health Care; 2002; 18(2):199-202. PubMed ID: 12053420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Selective serotonin reuptake inhibitors for major depression.
    Int J Technol Assess Health Care; 1998; 14(2):394-6. PubMed ID: 9611913
    [No Abstract]   [Full Text] [Related]  

  • 14. Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Photodynamic therapy.
    Int J Technol Assess Health Care; 1994; 10(4):711-3. PubMed ID: 7843892
    [No Abstract]   [Full Text] [Related]  

  • 15. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS); clarification of the CHAMPUS exclusion of unproven drugs, devices and medical treatments and procedures--DoD. Final rule.
    Fed Regist; 1997 Jan; 62(3):625-31. PubMed ID: 10164016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Civilian Health and Medical Program of the Uniformed Services (CHAMPUS); drug benefits; appropriate level of care provisions--Department of Defense. Final rule.
    Fed Regist; 1991 Nov; 56(228):59870-3. PubMed ID: 10115703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Funding the new biologics--what can we learn from infliximab? The CCOHTA report: a gastroenterologist's viewpoint.
    Hilsden R
    Can J Gastroenterol; 2002 Dec; 16(12):865-8. PubMed ID: 12522477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inappropriate use of DEA numbers.
    Lockey MW
    J Miss State Med Assoc; 1997 Nov; 38(11):425. PubMed ID: 9364119
    [No Abstract]   [Full Text] [Related]  

  • 20. Economic evaluation for pharmaceuticals in Germany.
    Jönsson B
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S1-2. PubMed ID: 17638033
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.